Bolt Biotherapeutics annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Bolt Biotherapeutics Depreciation & Amortization Growth & History (BOLT)
Bolt Biotherapeutics's depreciation and amortization was $1.3M for fiscal 2025.
View full Bolt Biotherapeutics company overviewBolt Biotherapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.3M | −$490,000 | −27.51% |
| 2024 | 2024-12-31 | $1.8M | −$73,000 | −3.94% |
| 2023 | 2023-12-31 | $1.9M | $188,000 | +11.28% |
| 2022 | 2022-12-31 | $1.7M | $473,000 | +39.65% |
| 2021 | 2021-12-31 | $1.2M | $582,000 | +95.25% |
| 2020 | 2020-12-31 | $611,000 | — | — |
Bolt Biotherapeutics quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $171,000 | −$176,000 | −50.72% |
| Q1 2026 | 2026-03-31 | $203,000 | −$196,000 | −49.12% |
| Q4 2025 | 2025-12-31 | $255,000 | — | — |
| Q3 2025 | 2025-09-30 | $290,000 | −$150,000 | −34.09% |
| Q2 2025 | 2025-06-30 | $347,000 | −$110,000 | −24.07% |
| Q1 2025 | 2025-03-31 | $399,000 | −$59,000 | −12.88% |
| Q3 2024 | 2024-09-30 | $440,000 | −$22,000 | −4.76% |
| Q2 2024 | 2024-06-30 | $457,000 | −$1,000 | −0.22% |
| Q1 2024 | 2024-03-31 | $458,000 | −$9,000 | −1.93% |
| Q3 2023 | 2023-09-30 | $462,000 | $23,000 | +5.24% |
| Q2 2023 | 2023-06-30 | $458,000 | $50,000 | +12.25% |
| Q1 2023 | 2023-03-31 | $467,000 | $110,000 | +30.81% |
| Q3 2022 | 2022-09-30 | $439,000 | $135,000 | +44.41% |
| Q2 2022 | 2022-06-30 | $408,000 | $152,000 | +59.38% |
| Q1 2022 | 2022-03-31 | $357,000 | $85,000 | +31.25% |
| Q3 2021 | 2021-09-30 | $304,000 | $125,000 | +69.83% |
| Q2 2021 | 2021-06-30 | $256,000 | $146,000 | +132.73% |
| Q1 2021 | 2021-03-31 | $272,000 | $171,000 | +169.31% |
| Q3 2020 | 2020-09-30 | $179,000 | — | — |
| Q2 2020 | 2020-06-30 | $110,000 | — | — |
| Q1 2020 | 2020-03-31 | $101,000 | — | — |
Bolt Biotherapeutics depreciation and amortization trends
Over the last five fiscal years, Bolt Biotherapeutics's depreciation and amortization increased from $611,000 to $1.3M, a change of $680,000. The latest reported quarter, Q2 2026, shows $171,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bolt Biotherapeutics source filings ↗